Psychemedics Corporation (PMD)
USD 2.67
(0.0%)
USD 2.67
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 945 Thousand USD | -57.87% |
| 2022 | 2.24 Million USD | -35.53% |
| 2021 | 3.47 Million USD | -52.6% |
| 2020 | 7.33 Million USD | 69.65% |
| 2019 | 4.32 Million USD | 256.93% |
| 2018 | 1.21 Million USD | -49.92% |
| 2017 | 2.42 Million USD | 8.18% |
| 2016 | 2.23 Million USD | -47.64% |
| 2015 | 4.27 Million USD | -11.88% |
| 2014 | 4.84 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 200 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | -100.0% |
| 1993 | 200 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| 1989 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 623 Thousand USD | 0.0% |
| 2024 Q1 | 687 Thousand USD | 0.0% |
| 2023 Q1 | 1.95 Million USD | -13.02% |
| 2023 FY | 945 Thousand USD | -57.87% |
| 2023 Q4 | 945 Thousand USD | -26.34% |
| 2023 Q3 | 1.28 Million USD | -20.8% |
| 2023 Q2 | 1.62 Million USD | -16.97% |
| 2022 Q4 | 2.24 Million USD | -13.06% |
| 2022 Q2 | 2.91 Million USD | -8.58% |
| 2022 Q1 | 3.18 Million USD | -8.51% |
| 2022 FY | 2.24 Million USD | -35.53% |
| 2022 Q3 | 2.58 Million USD | -11.34% |
| 2021 Q4 | 3.47 Million USD | -12.46% |
| 2021 Q2 | 6.58 Million USD | -6.28% |
| 2021 FY | 3.47 Million USD | -52.6% |
| 2021 Q1 | 7.02 Million USD | -4.25% |
| 2021 Q3 | 3.97 Million USD | -39.66% |
| 2020 Q1 | 3.99 Million USD | -7.67% |
| 2020 Q4 | 7.33 Million USD | -4.64% |
| 2020 FY | 7.33 Million USD | 69.65% |
| 2020 Q2 | 8.09 Million USD | 102.63% |
| 2020 Q3 | 7.69 Million USD | -4.91% |
| 2019 Q3 | 3.26 Million USD | 109.04% |
| 2019 Q1 | 1.75 Million USD | 45.05% |
| 2019 FY | 4.32 Million USD | 256.93% |
| 2019 Q4 | 4.32 Million USD | 32.66% |
| 2019 Q2 | 1.56 Million USD | -11.26% |
| 2018 Q2 | 1.94 Million USD | -10.96% |
| 2018 Q1 | 2.18 Million USD | -9.88% |
| 2018 FY | 1.21 Million USD | -49.92% |
| 2018 Q3 | 1.71 Million USD | -11.48% |
| 2018 Q4 | 1.21 Million USD | -29.49% |
| 2017 Q1 | 1.95 Million USD | -12.78% |
| 2017 Q3 | 928 Thousand USD | -12.7% |
| 2017 Q4 | 2.42 Million USD | 160.78% |
| 2017 FY | 2.42 Million USD | 8.18% |
| 2017 Q2 | 1.06 Million USD | -45.52% |
| 2016 Q4 | 2.23 Million USD | -35.8% |
| 2016 Q1 | 4.35 Million USD | 1.94% |
| 2016 Q3 | 3.48 Million USD | -11.11% |
| 2016 FY | 2.23 Million USD | -47.64% |
| 2016 Q2 | 3.91 Million USD | -10.0% |
| 2015 FY | 4.27 Million USD | -11.88% |
| 2015 Q3 | 4.67 Million USD | 12.75% |
| 2015 Q4 | 4.27 Million USD | -8.66% |
| 2015 Q2 | 4.14 Million USD | -7.78% |
| 2015 Q1 | 4.49 Million USD | -7.22% |
| 2014 Q1 | 842.35 Thousand USD | 0.0% |
| 2014 Q4 | 4.84 Million USD | -6.73% |
| 2014 Q3 | 5.19 Million USD | 10.24% |
| 2014 Q2 | 4.71 Million USD | 459.75% |
| 2014 FY | 4.84 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q2 | - USD | 0.0% |
| 1999 FY | 200 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | 200 Thousand USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | -50.0% |
| 1994 FY | - USD | -100.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q4 | - USD | -100.0% |
| 1993 Q1 | 300 Thousand USD | 0.0% |
| 1993 Q2 | 200 Thousand USD | -33.33% |
| 1993 Q3 | 200 Thousand USD | 0.0% |
| 1993 Q4 | 200 Thousand USD | 0.0% |
| 1993 FY | 200 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 69.258% |
| Applied DNA Sciences, Inc. | 739.16 Thousand USD | -27.847% |
| Aspira Women's Health Inc. | 1.43 Million USD | 33.916% |
| Biodesix, Inc. | 35.22 Million USD | 97.317% |
| BioNexus Gene Lab Corp. | 98.76 Thousand USD | -856.836% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | 15.509% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | 15.509% |
| Bionano Genomics, Inc. | 7.17 Million USD | 86.829% |
| CareDx, Inc | 28.27 Million USD | 96.658% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 14.19 Million USD | 93.344% |
| DarioHealth Corp. | 24.59 Million USD | 96.157% |
| Exact Sciences Corporation | 2.47 Billion USD | 99.962% |
| Fulgent Genetics, Inc. | 10.11 Million USD | 90.654% |
| Guardant Health, Inc. | 1.13 Billion USD | 99.917% |
| ICON Public Limited Company | 3.66 Billion USD | 99.974% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | 99.848% |
| Illumina, Inc. | 1.48 Billion USD | 99.937% |
| Intelligent Bio Solutions Inc. | 81.32 Thousand USD | -1062.019% |
| iSpecimen Inc. | 29.13 Thousand USD | -3144.078% |
| Standard BioTools Inc. | 3.98 Million USD | 76.274% |
| MDxHealth SA | 35.56 Million USD | 97.343% |
| 23andMe Holding Co. | 67.84 Million USD | 98.607% |
| Medpace Holdings, Inc. | 142.12 Million USD | 99.335% |
| Myriad Genetics, Inc. | 130.9 Million USD | 99.278% |
| Mainz Biomed B.V. | 2.19 Million USD | 56.965% |
| ENDRA Life Sciences Inc. | 192.06 Thousand USD | -392.029% |
| NeoGenomics, Inc. | 606.06 Million USD | 99.844% |
| Neogen Corporation | 888.39 Million USD | 99.894% |
| Inotiv, Inc. | 399.4 Million USD | 99.763% |
| Natera, Inc. | 282.94 Million USD | 99.666% |
| OpGen, Inc. | 2.02 Million USD | 53.255% |
| OPKO Health, Inc. | 222.03 Million USD | 99.574% |
| Prenetics Global Limited | 867.21 Thousand USD | -8.97% |
| Prenetics Global Limited | 867.21 Thousand USD | -8.97% |
| Precipio, Inc. | 106 Thousand USD | -791.509% |
| Personalis, Inc. | 1.23 Million USD | 23.42% |
| RadNet, Inc. | 812.06 Million USD | 99.884% |
| Sera Prognostics, Inc. | 840 Thousand USD | -12.5% |
| Sotera Health Company | 2.22 Billion USD | 99.958% |
| Neuronetics, Inc. | 59.28 Million USD | 98.406% |
| Star Equity Holdings, Inc. | 1.14 Million USD | 17.467% |
| Star Equity Holdings, Inc. | 1.14 Million USD | 17.467% |
| Trinity Biotech plc | 54.65 Million USD | 98.271% |
| T2 Biosystems, Inc. | 6.59 Million USD | 85.677% |
| Twist Bioscience Corporation | 79.17 Million USD | 98.806% |
| Exagen Inc. | 19.23 Million USD | 95.086% |